Report: China Independent Clinical Laboratory Industry Report, 2014-2017
Albany, NY (PRWEB) October 27, 2014
The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there was around RMB3.5 billion, up as much as 70% yr-on-yr, yet only accounting for 2%-3% of the total revenue of medical diagnosis.
View Full Report at http://www.marketresearchreports.biz/analysis/226611
There are about 110 independent clinical laboratories in today’s China, but most of them are small sized. KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene as the strong performers thereof hold a combined market share of roughly 70%.
Because of a high requirement on the samples within a shorter time limit for place, the industry has a certain service radius. Therefore, a national layout is essential to business development and customer acquisition and chain-orientation the key development mode, for enterprises. KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene have by far 19, 15, 14 and 8 independent medical laboratories across the country.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/226611
KingMed Diagnostics as the largest independent clinical laboratory enterprise in China enjoys a market share of approximately 40%, receiving recognition from both College of American Pathologists (CAP) and ISO15189. In the first half of 2014 it posted revenue of RMB846 million, up 37% yr-on-yr. Equipped with detection platforms for tumor diseases, genetic diseases, blood diseases, etc., KingMed Diagnostics will give top priority to tumor, reproduction and microbiological testing in the future.
ADICON is the first independent medical laboratory in domestic trans-regional chain operation, with a market share as high as 15%-18%. In recent years, many of its subsidiaries have successively won ISO15189 and CAP certificates
Explore All China Market Research Reports at http://www.marketresearchreports.biz/country/China
As an industry leader in the business model of "service + agent", DIAN Diagnostics gets involved in independent clinical laboratory, judicial expertise, diagnostic products agency and other areas. Currently, the company boasts an 18% market share in the Chinese independent clinical laboratory industry, capable of carrying out more than 1,000 medical diagnostic services.
Moreover, related enterprises abroad have also been well aware of the growth potential in China’s independent clinical laboratory industry, and set foot in the Chinese market via cooperation with local companies.
In February 2012, Quest and KingMed Diagnostics entered into a strategic alliance and established the KingMed&Quest Diagnostics Alliance Laboratory. And the Tianbo Lab jointly set up bythe South Korea-based SK Group and Xi’an Tianlong Science & Technology Co.Ltd started business in July 2014.
Global And China Monoclonal Antibody Industry Report, 2014-2019
View Full Report at http://www.marketresearchreports.biz/analysis/226440
Global blockbuster monoclonal antibody agents are still concentrated in Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson, Novartis, etc. In 2013, the top 10 best-selling monoclonal antibody agents (Humira, Remicade, Enbrel, Rituxa, Avastin, Herceptin, Lucents, Synagis, Prolia/Xgeva and Erbitux, in order) mostly came from these companies mentioned above. Global sales of these ten monoclonal antibody agents totaled about USD 58.1 billion in 2013, and are predicted to amount to USD 64.1 billion in 2014.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/226440
These companies construct mature monoclonal antibody R&D platform, have unparalleled technical advantages in a series of processes including the selection of target gene, genetic sequencing, construction of monoclonal antibody structure and industrialized production, and are well-capitalized (R&D costs of these companies accounted for 15%-20% of revenue during the same period.). It is expected that they will keep a leading position in global monoclonal antibody market over the next five to ten years.
Global And China DNA Sequencing Industry Research Report, 2014-2017
View Full Report at http://www.marketresearchreports.biz/analysis/225746
DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a broad range of fields, including medicine, biology, geology, and agriculture.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/225746
With the advancement of DNA sequencing technology and dramatic decline in sequencing costs, DNA sequencing is increasingly showing its market potential in noninvasive detection, disease diagnosis, and personalized treatment. In 2013, the market size of global DNA sequencing (including equipment and consumables, service and workflow, etc.) approximated USD4.6 billion, up around 26% from the previous year. It is projected that by 2017 this figure will reach USD10.096 billion, exceeding USD10 billion for the first time.
Global And China Stem Cell Industry Report, 2014-2017
View Full Report at http://www.marketresearchreports.biz/analysis/223134
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/223134
Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.
Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Browse Blog at http://businessmonitorinternational.wordpress.com/